CN117865993A - AAK1 inhibitor and preparation and application thereof - Google Patents
AAK1 inhibitor and preparation and application thereof Download PDFInfo
- Publication number
- CN117865993A CN117865993A CN202410031946.8A CN202410031946A CN117865993A CN 117865993 A CN117865993 A CN 117865993A CN 202410031946 A CN202410031946 A CN 202410031946A CN 117865993 A CN117865993 A CN 117865993A
- Authority
- CN
- China
- Prior art keywords
- compound
- site
- reaction
- following structures
- carrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 229940119498 AAK1 inhibitor Drugs 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 231
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims description 48
- 238000006243 chemical reaction Methods 0.000 claims description 30
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 13
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 12
- 238000006722 reduction reaction Methods 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 11
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims description 10
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 claims description 10
- 238000000297 Sandmeyer reaction Methods 0.000 claims description 8
- 229940125890 compound Ia Drugs 0.000 claims description 6
- 230000002140 halogenating effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 230000003281 allosteric effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 47
- 239000007787 solid Substances 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 19
- 230000002829 reductive effect Effects 0.000 description 17
- -1 g Chemical class 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000002274 desiccant Substances 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 241000711573 Coronaviridae Species 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 241001678559 COVID-19 virus Species 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 6
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 5
- RKAHOQATMSONTM-IBGZPJMESA-N FC(C1=NC=CC(=C1)C1=NC(=C(C=C1)OC[C@](CC(C)C)(N)C)C(F)F)F Chemical compound FC(C1=NC=CC(=C1)C1=NC(=C(C=C1)OC[C@](CC(C)C)(N)C)C(F)F)F RKAHOQATMSONTM-IBGZPJMESA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229940126142 compound 16 Drugs 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000000967 suction filtration Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 208000001528 Coronaviridae Infections Diseases 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 229940126296 BMS-986176 Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102100022972 Transcription factor AP-2-alpha Human genes 0.000 description 2
- 101710189834 Transcription factor AP-2-alpha Proteins 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006395 clathrin-mediated endocytosis Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 239000011981 lindlar catalyst Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YNQNYIHMAZLJAV-UHFFFAOYSA-N tert-butyl n-[2-[[3-(4-carbamoylphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]-n-methylcarbamate Chemical compound N12N=C(NCCN(C)C(=O)OC(C)(C)C)C=CC2=NC=C1C1=CC=C(C(N)=O)C=C1 YNQNYIHMAZLJAV-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- SLTBMTIRYMGWLX-XMMPIXPASA-N (2r)-2-[(4-chloroanilino)carbamoylamino]-3-(1h-indol-3-yl)-n-(2-phenylethyl)propanamide Chemical compound C1=CC(Cl)=CC=C1NNC(=O)N[C@@H](C(=O)NCCC=1C=CC=CC=1)CC1=CNC2=CC=CC=C12 SLTBMTIRYMGWLX-XMMPIXPASA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- RXNPEQZHMGFNAY-GEALJGNFSA-N (5R)-4-[(1S,6R)-5-[(2S)-2-(4-chlorophenyl)-3-(propan-2-ylamino)propanoyl]-2,5-diazabicyclo[4.1.0]heptan-2-yl]-5-methyl-6,8-dihydro-5H-pyrido[2,3-d]pyrimidin-7-one Chemical compound C[C@@H]1CC(=O)NC2=C1C(=NC=N2)N3CCN([C@H]4[C@@H]3C4)C(=O)[C@H](CNC(C)C)C5=CC=C(C=C5)Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- OXTVBHDILDPYAS-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-[3-(3-hydroxypropoxy)phenyl]-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OCCCO)=C1 OXTVBHDILDPYAS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HNFMVVHMKGFCMB-UHFFFAOYSA-N 3-[3-[4-(1-aminocyclobutyl)phenyl]-5-phenylimidazo[4,5-b]pyridin-2-yl]pyridin-2-amine Chemical compound NC1=NC=CC=C1C1=NC2=CC=C(C=3C=CC=CC=3)N=C2N1C1=CC=C(C2(N)CCC2)C=C1 HNFMVVHMKGFCMB-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 238000003727 ADP Glo Kinase Assay Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710114810 Glycoprotein Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NPUXORBZRBIOMQ-RUZDIDTESA-N [(2R)-1-[[4-[[3-(benzenesulfonylmethyl)-5-methylphenoxy]methyl]phenyl]methyl]-2-pyrrolidinyl]methanol Chemical compound C=1C(OCC=2C=CC(CN3[C@H](CCC3)CO)=CC=2)=CC(C)=CC=1CS(=O)(=O)C1=CC=CC=C1 NPUXORBZRBIOMQ-RUZDIDTESA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an AAK1 inhibitor, and preparation and application thereof. The invention provides an AAK1 inhibitor with a novel structure shown in a formula (I), a pharmaceutical composition and a hydrate containing the compound shown in the formula (I), and isotope derivatives, chiral isomers, allosteric isomers, different salts, prodrugs, preparations and the like of the compound. The invention also provides a preparation method and application of the AAK1 inhibitor with novel structure.
Description
Technical Field
The invention belongs to the technical field of synthesis of anti-coronavirus drugs, and particularly relates to an AAK1 inhibitor, and preparation and application thereof.
Background
There are 6 links in infection replication of coronaviruses: (1) Attachment, i.e., attachment of the viral S glycoprotein to a specific receptor on the surface of a host cell, occurs with specific binding; (2) Invasion, i.e., into a cell of a host by endocytosis or membrane fusion; (3) Uncoating, i.e., the capsid of the virus is degraded and destroyed by the host cell or the virus' own enzymes, releasing the viral nucleic acid; (4) Synthesis, i.e., the replication of RNA and the synthesis of viral proteins within the host cell; (5) Assembling, namely assembling each part of the synthesized nucleic acid, protein capsids and the like into new virus particles; (6) The newly produced virions leave the host cell by blebbing. In each of the above links, coronavirus invasion is a crucial step. Successful intervention in this step, the virus can be rejected from the host cell. The known mode of endocytosis is mainly clathrin-dependent endocytosis.
AAK1 is a serine-threonine kinase, is a key kinase for threonine phosphorylation at 156 th subunit mu 2 of AP-2 protein, and the phosphorylated AP-2 protein mediates clathrin-dependent endocytosis, so that AAK1 can be effectively inhibited and blocked, thereby playing a role in preventing coronaviruses from entering host cells and achieving the effect of killing viruses.
Disclosure of Invention
It is a first object of the present invention to address the deficiencies of the prior art and to provide an AAK1 inhibitor compound.
An AAK1 inhibitor compound, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, having the structure shown in formula (I):
x in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site of Y to Z linkage;
preferably, an AAK1 inhibitor compound, or an optical isomer, racemate, single enantiomer, possible diastereoisomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, has a structural formula shown in formula (I);
x in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site of Y to Z linkage;
more preferably, an AAK1 inhibitor compound, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, has a structural formula shown in formula (I);
x in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site of Y to Z linkage;
most preferably, the compound has a structural formula as shown in any one of formulas 1 to 27:
a second object of the present invention is to provide a method for preparing an AAK1 inhibitor.
When (when)Or->When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out a Sonogashira reaction on the compound h and the compound i to obtain a compound Ia;
the synthetic route is as follows:
when A in the compound h is Br, X in the formula (I) is selected fromIs the case for (a);
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
When (when)Or->When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out a Sonogashira reaction on the compound h and the compound i to obtain a compound Ia;
(7) The compound Ia is subjected to reduction reaction to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
When (when)When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) The compound e is subjected to Miyaurabelation reaction to obtain a compound f;
(5) Reacting the compound g with the compound h through decarboxylative Knoevenagel to obtain a compound i;
(6) Carrying out Suzuki reaction on the compound f and the compound I to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
When (when)When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) The compound e is subjected to Miyaurabelation reaction to obtain a compound f;
(5) Carrying out amide coupling reaction on the compound g and the compound h to obtain a compound i;
(6) Carrying out Suzuki reaction on the compound f and the compound I to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3, y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
When (when)When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) The compound d undergoes bromine substitution reaction to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out Suzuki reaction on the compound h and the compound i to obtain a compound Ib;
the synthetic route is as follows:
wherein,selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
The compound represented by the formula (I) of the present invention can be produced by the above-mentioned method, however, the conditions of the method, such as reactants, solvents, amounts of the compounds used, reaction temperature, time required for the reaction, etc., are not limited to the above-mentioned explanation. The compounds of the present invention may also optionally be conveniently prepared by combining the various synthetic methods described in this specification or known in the art, such combinations being readily apparent to those skilled in the art to which the present invention pertains.
A third object of the present invention is to provide the use of the above AAK1 inhibitor compounds, or optical isomers, racemates, single enantiomers, possible diastereomers thereof, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates thereof, for the preparation of an anti-coronavirus medicament.
A fourth object of the present invention is to provide an anti-coronavirus drug containing a safe and effective amount of the AAK1 inhibitor compound of novel structure, or an optical isomer, a racemate, a single enantiomer, a possible diastereomer, or a pharmaceutically acceptable salt, a prodrug, a deuterated derivative, a hydrate, or a solvate thereof.
Preferably, the anti-coronavirus drug may further comprise a pharmaceutically acceptable carrier.
Pharmaceutical compositions and methods of administration
Because the compounds of the present invention have activity in inhibiting invasion of various coronaviruses, the compounds of the present invention and various crystalline forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates thereof, and pharmaceutical compositions containing the compounds of the present invention as main active ingredients are useful for treating, preventing and alleviating various diseases caused by coronaviruses.
The pharmaceutical compositions of the present invention comprise a safe and effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical compositions contain 1-2000mg of the compound of the invention per dose, more preferably 5-1000mg of the compound of the invention per dose. Preferably, the "one dose" is a capsule or tablet.
"pharmaceutically acceptable carrier" means: one or more compatible solid or liquid filler or gel materials which are suitable for human use and must be of sufficient purity and sufficiently low toxicity. "compatible" as used herein means that the components of the composition are capable of blending with and between the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmaceutically acceptable carrier moieties are cellulose and its derivatives (e.g., sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, and the like), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, and the like), polyols (e.g., propylene glycol, glycerol, mannitol, sorbitol, and the like), emulsifiers (e.g.) Wetting agents (such as sodium lauryl sulfate), coloring agents, flavoring agents, stabilizing agents, antioxidants, preservatives, pyrogen-free water and the like.
The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) and topical administration.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or solubilisers, such as starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, such as glycerin; (d) Disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) slow solvents such as paraffin; (f) absorption accelerators, such as quaternary amine compounds; (g) humectants, such as cetyl alcohol and glycerol monostearate; (h) adsorbents such as kaolin; (i) Lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents.
Solid dosage forms, such as tablets, dragees, capsules, pills, and granules, can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain location within the gut. Examples of embedding components that can be used are polymeric substances and waxy substances. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances and the like.
In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar or mixtures of these substances, and the like.
Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredients are mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required if necessary.
The compounds of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
When a pharmaceutical composition is used, a safe and effective amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, wherein the dose at the time of administration is a pharmaceutically effective dose, and the daily dose is usually 1 to 5000mg, preferably 5 to 2000mg, for a human having a body weight of 60 kg. Of course, the particular dosage should also take into account factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled practitioner.
Compared with the prior art, the invention has the main advantages that: provided are novel AAK1 inhibitors of the structure shown in formula (I), pharmaceutical compositions and hydrates of the compounds of formula (I), and optical isomers, racemates, single enantiomers, possible diastereomers of the compounds, or pharmaceutically acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates thereof. The invention also provides a preparation method of the AAK1 inhibitor with novel structure, and activity of inhibiting various coronaviruses and application of the AAK1 inhibitor in resisting coronaviruses. The AAK1 inhibitor with novel structure is expected to become candidate anti-coronavirus drugs.
Drawings
FIG. 1 shows the results of green fluorescent protein expression under a fluorescent microscope in example 22.
FIG. 2 shows the results of luciferase assay in example 22.
Detailed Description
The invention will be further described with reference to the following specific examples, but the scope of the invention is not limited thereto:
example 1: preparation of Compound 1
To a solution of compound 1b (10.0 g,64.94 mmol) and potassium hydroxide (KOH, 85%,12.0g,216.45 mmol) in dimethyl sulfoxide (DMSO, 100.0 mL) was added compound 1a (8.0 mL,72.15 mmol). After the addition, the reaction mixture was stirred at room temperature for 3 hours, heated to 60℃and stirred for 24 hours. The reaction solution is cooled to room temperature, and is slowly dripped into ice water under stirring, and the precipitated solid product is collected by suction filtration. The solid was dissolved in Dichloromethane (DCM), washed twice with water and then once with saturated brine, and the organic phase was washed with anhydrous sodium sulfate (Na 2 SO 4 ) And (5) drying. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure, and the obtained crude product was recrystallized from Ethyl Acetate (EA) to give compound 1c (8.1 g, yield 52.9%) as a yellow solid.
To compound 1c (10.0 g,42.37 mmol) and ammonium chloride (NH) with stirring 4 Cl,6.7g,127.12 mmol) ethanol (EtOH, 100.0 mL) and water (H 2 To the mixed solution of O,25.0 mL) was added iron powder (Fe, 11.9g,211.87 mmol). After the addition, the reaction mixture was heated to 70℃and stirred overnight. The reaction was cooled to room temperature, the buchner funnel was filled with celite, filtered off with suction and the filter cake was washed with DCM. The filtrate was concentrated under reduced pressure. The solid was dissolved in DCM, washed twice with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (EA/pe+0.5% ammonia water system elution) to give compound 1d (6.3 g, 72.2%) as a pale yellow solid.
To H of Compound 1d (5.2 g,25.0 mmol) in an ice bath 2 An aqueous solution (48%, 85.0 mL) of hydrogen bromide was added to a solution of O (50.0 mL), followed by dropwise addition of sodium nitrite (NaNO) 2 ) H of (2) 2 O solution (17.0 mL,1 g/mL). After the addition, the reaction was stirred in an ice bath for 40 minutes and then cuprous bromide (CuBr, 7.2g,50.0 mmol) was added. After the reaction mixture was heated to 60℃and stirred for 15 minutes, copper bromide (CuBr) was added thereto 2 11.2g,50.0 mmol). After the addition, the reaction mixture was stirred at 60℃overnight. The reaction solution was cooled to room temperature, and an appropriate amount of EA was added thereto, followed by stirring with saturated potassium carbonate (K) 2 CO 3 ) And (3) an aqueous solution until no bubbles are generated in the reaction solution. The buchner funnel was filled with celite, the solids were removed by suction filtration, and the filtrate was transferred to a separatory funnel. Separating the organic phase and the aqueous phase, extracting the aqueous phase with EA twice, combining the organic phases, washing the combined phases with saturated brine once, and washing the combined phases with anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure, and the obtained crude product was purified by silica gel column chromatography (eluting with EA/PE system) to give compound 1e (3.1 g, yield 46.2%) as a white solid.
To compound 1e (1.1 g,4.0 mmol), compound 1f (1.2 g,4.8 mmol) and K 2 CO 3 (1.7 g,12.0 mmol) dioxane (dioxane, 40.0 mL) and H 2 A nitrogen stream was introduced into the mixed solution of O (10.0 mL) to purge the reaction mixture of air (15 min), and then XPhos Pd G3 (338 mg,0.4 mmol) as a catalyst was added. After the addition, the reaction mixture was heated to 90℃in a closed system and stirred overnight. The reaction solution was cooled to room temperature, the solution was concentrated under reduced pressure, the resulting solid was dissolved in DCM, washed twice with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to give 1g (1.0 g, 84.2% yield) of a pale yellow solid compound.
N-bromosuccinimide (NBS, 107mg,0.6 mmol) was added in portions to a solution of compound 1g (154 mg,0.5 mmol) in DCM (15.0 mL) under ice-bath. After the addition, the reaction solution was reacted in an ice bath for 2.5 hours. The reaction was diluted with the appropriate amount of DCM and concentrated in saturated sodium bicarbonate (NaHCO 3 ) Washing with aqueous solution once, then washing with saturated saline, and washing the organic phase with anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to give compound 1 (123 mg, yield 63.8%) as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.09(s,1H),8.53(d,J=2.1Hz,1H),7.91(d,J=2.0Hz,1H),7.73(d,J=2.6Hz,1H),7.20(dd,J=8.4,2.2Hz,1H),7.11(d,J=2.2Hz,1H),6.95(d,J=8.6Hz,1H),4.26(dd,J=10.6,2.5Hz,1H),4.03–3.95(m,1H),3.95–3.84(m,2H),3.63(td,J=11.5,8.4Hz,2H),3.24–3.11(m,2H),2.73(td,J=12.1,3.6Hz,1H).
Example 2: preparation of Compound 2
N-iodosuccinimide (NIS, 743mg,3.3 mmol) was added in portions to a solution of compound 1g (921 mg,3.0 mmol) in DCM (90.0 mL) under ice-bath. After the addition, the reaction solution was stirred in an ice bath for 2.5 hours. The precipitated solid product was collected by suction filtration to give compound 2a (800 mg, yield 61.6%) as a pale yellow solid.
A solution of compound 2a (173 mg,0.4 mmol), compound 2b (45 mg,0.44 mmol) and triethylamine (0.17 mL,1.2 mmol) in N, N-dimethylformamide (DMF, 4.0 mL) was purged with a stream of nitrogen for 15min, and then catalyst Pd (PPh) 3 ) 2 Cl 2 (28 mg,0.04 mmol) and copper iodide (CuI, 15mg,0.08 mmol). After the addition, the reaction was stirred overnight at room temperature under nitrogen. The reaction solution was diluted with an appropriate amount of DCM, washed three times with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to give compound 2 (50 mg, 30.7% yield) as a white solid. 1 H NMR(400MHz,DMSO-d 6 )δ12.19(d,J=2.1Hz,1H),8.54(d,J=1.8Hz,1H),8.17(d,J=2.0Hz,1H),7.94(d,J=2.5Hz,1H),7.64–7.56(m,2H),7.48–7.34(m,3H),7.24(dd,J=8.4,2.1Hz,1H),7.14(d,J=2.1Hz,1H),6.97(d,J=8.5Hz,1H),4.27(dd,J=10.6,2.3Hz,1H),4.04–3.85(m,3H),3.72–3.56(m,2H),3.25–3.10(m,2H),2.79–2.65(m,1H).
Example 3: preparation of Compound 3
Referring to the procedure for the synthesis of compound 2 in example 2, compound 3 (40 mg, 33.8%) was obtained as a yellow solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.31(s,1H),8.61(d,J=24.9Hz,2H),8.17(s,1H),8.05(d,J=2.6Hz,1H),7.84(t,J=7.6Hz,1H),7.72(d,J=7.0Hz,1H),7.38(s,1H),7.24(dd,J=8.3,2.0Hz,1H),7.14(d,J=2.1Hz,1H),6.97(d,J=8.5Hz,1H),4.27(dd,J=10.6,2.4Hz,1H),4.03–3.95(m,1H),3.95–3.87(m,2H),3.69–3.59(m,2H),3.23–3.13(m,2H),2.79–2.68(m,1H).
Example 4: preparation of Compound 4
Referring to the procedure for the synthesis of compound 2 in example 2, compound 4 (48 mg, 29.4%) was obtained as a pale yellow solid. 1 H NMR(400MHz,DMSO-d 6 )δ12.27(d,J=2.2Hz,1H),8.83(s,1H),8.56(d,J=1.8Hz,2H),8.23(d,J=2.0Hz,1H),8.06–7.95(m,2H),7.46(dd,J=7.8,4.8Hz,1H),7.25(dd,J=8.4,2.1Hz,1H),7.16(d,J=2.1Hz,1H),6.98(d,J=8.5Hz,1H),4.27(dd,J=10.6,2.3Hz,1H),4.05–3.85(m,3H),3.72–3.57(m,2H),3.25–3.11(m,2H),2.80–2.66(m,1H).
Example 5: preparation of Compound 5
Referring to the procedure for the synthesis of compound 2 in example 2, compound 5 (48 mg, 29.4%) was obtained as a white solid. 1 H NMR(400MHz,DMSO-d 6 )δ12.36(d,J=2.3Hz,1H),8.70–8.58(m,2H),8.57(d,J=2.1Hz,1H),8.24(d,J=2.0Hz,1H),8.06(d,J=2.7Hz,1H),7.59(d,J=5.9Hz,2H),7.25(dd,J=8.4,2.1Hz,1H),7.16(d,J=2.1Hz,1H),6.98(d,J=8.5Hz,1H),4.28(dd,J=10.6,2.4Hz,1H),4.04–3.85(m,3H),3.73–3.58(m,2H),3.25–3.12(m,2H),2.79–2.65(m,1H).
Example 6: preparation of Compound 6
To Compound 4 (61 mg,0.15 mmol) in methanol (CH 3 To the OH,5.0 mL) solution was added Lindlar catalyst (10 mg). After the addition was completed, the air was replaced with hydrogen three times, and the reaction solution was stirred at 60℃overnight in a hydrogen atmosphere. The reaction solution is prepared with a proper amount of CH 3 OH was diluted, lindlar catalyst was removed by suction filtration, the filtrate was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (EA/PE system elution) to give compound 6 (20 mg, yield 32.5%) as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ11.93(d,J=2.1Hz,1H),8.81(d,J=1.8Hz,1H),8.56(d,J=1.7Hz,1H),8.40(d,J=2.0Hz,1H),8.06(d,J=8.0Hz,1H),7.83(d,J=2.5Hz,1H),7.45(d,J=2.0Hz,1H),6.98(d,J=8.5Hz,1H),6.94(d,J=12.1Hz,1H),6.89(d,J=8.5Hz,1H),6.86(dd,J=8.4,2.0Hz,1H),6.78(d,J=2.0Hz,1H),6.55(d,J=12.1Hz,1H),4.26(ddd,J=15.5,10.6,2.6Hz,2H),4.01–3.85(m,5H),3.63(ddd,J=12.4,6.4,3.7Hz,2H).
Example 7: preparation of Compound 7
Referring to the procedure for the synthesis of compound 6 in example 6, compound 7 (20 mg, yield 19.4%) was obtained as an off-white solid. 1 H NMR(500MHz,DMSO-d 6 )δ11.34–11.26(m,1H),8.46(s,1H),8.39(d,J=2.0Hz,2H),8.05(d,J=2.0Hz,1H),7.72–7.65(m,1H),7.29(dd,J=7.8,4.8Hz,1H),7.22(d,J=2.0Hz,1H),7.16(dd,J=8.4,2.2Hz,1H),7.08(d,J=2.1Hz,1H),6.95(d,J=8.6Hz,1H),4.26(dd,J=10.6,2.6Hz,1H),3.98(dd,J=10.3,3.0Hz,1H),3.94–3.86(m,2H),3.70–3.58(m,2H),3.14(ddd,J=13.2,7.2,2.7Hz,1H),3.07–3.02(m,2H),3.02–2.96(m,2H).
Example 8: preparation of Compound 8
To compound 1 (193 mg,0.5 mmol), compound 8a (123 mg,0.6 mmol) and K 2 CO 3 (207 mg,1.5 mmol) of dioxane (5.0 mL) and H 2 A mixed solution of O (1.5 mL) was purged with nitrogen (15 min), and then catalyst Pd (PPh) was added 3 ) 4 (58 mg,0.05 mmol). After the addition, the reaction mixture was stirred overnight in a closed system at 90 ℃. The reaction solution was cooled to room temperature, the solution was concentrated under reduced pressure, the resulting solid was dissolved in DCM, washed twice with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to give compound 8 (20 mg, yield 10.4%) as a pale yellow solid. 1 H NMR(400MHz,DMSO-d 6 )δ12.23–12.00(m,1H),9.03(d,J=2.0Hz,1H),8.52(d,J=1.9Hz,1H),8.47(dd,J=4.7,1.4Hz,1H),8.36(d,J=1.9Hz,1H),8.22(dt,J=7.9,1.8Hz,1H),8.05(d,J=2.4Hz,1H),7.47(dd,J=7.8,4.8Hz,1H),7.24(dd,J=8.4,2.1Hz,1H),7.17(d,J=2.1Hz,1H),6.97(d,J=8.5Hz,1H),4.27(dd,J=10.6,2.4Hz,1H),4.05–3.96(m,1H),3.95–3.85(m,2H),3.73–3.58(m,2H),3.25–3.09(m,2H),2.79–2.64(m,1H).
Example 9: preparation of Compound 9
Referring to the synthetic procedure for compound 2 in example 2, compound 9 (43 mg, 10.2%) was obtained as a pale yellow solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.06(s,1H),8.53(s,1H),8.26(s,1H),8.12–8.09(m,1H),7.83(d,J=2.5Hz,1H),7.56(d,J=8.6Hz,1H),7.22(dd,J=8.4,2.1Hz,1H),7.12(d,J=2.1Hz,1H),6.96(d,J=8.5Hz,1H),6.51(s,1H),6.33(s,2H),4.26(dd,J=10.6,2.5Hz,1H),3.98(dd,J=10.7,3.0Hz,1H),3.93–3.86(m,2H),3.68–3.59(m,2H),3.23–3.11(m,2H),2.73(td,J=11.1,10.4,3.2Hz,1H).
Example 10: preparation of Compound 10
Referring to the procedure for the synthesis of compound 2 in example 2, compound 10 (81 mg, 19.2%) was obtained as a brown solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.11–12.04(m,1H),8.53(s,1H),8.18(d,J=1.7Hz,1H),7.91(d,J=2.6Hz,1H),7.29(dd,J=7.6,1.4Hz,1H),7.23(dd,J=8.4,2.1Hz,1H),7.13(d,J=2.1Hz,1H),7.09–7.03(m,1H),6.96(d,J=8.5Hz,1H),6.77–6.73(m,1H),6.56(td,J=7.5,1.0Hz,1H),5.43(s,2H),4.26(dd,J=10.6,2.5Hz,1H),3.98(dd,J=10.6,3.3Hz,1H),3.92–3.86(m,2H),3.72–3.57(m,3H),3.21–3.13(m,2H).
Example 11: preparation of Compound 11
Referring to the synthetic procedure for compound 2 in example 2, compound 11 (298 mg, 42.4%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.12(d,J=2.2Hz,1H),8.53(d,J=2.0Hz,1H),8.08(d,J=2.1Hz,1H),7.89(d,J=2.8Hz,1H),7.22(dd,J=8.4,2.1Hz,1H),7.12(d,J=2.1Hz,1H),7.05(t,J=7.8Hz,1H),6.97(d,J=8.6Hz,1H),6.80–6.76(m,1H),6.72(d,J=7.6Hz,1H),6.57(ddd,J=8.1,2.2,0.8Hz,1H),5.24(s,1H),4.27(dd,J=10.6,2.5Hz,1H),3.99(dd,J=10.7,3.1Hz,1H),3.95–3.87(m,2H),3.71–3.59(m,2H),3.24–3.12(m,2H),2.74(td,J=11.3,10.7,3.4Hz,1H).
Example 12: preparation of Compound 12
Referring to the synthetic procedure of compound 2 in example 2, compound 12 (67 mg, 10.6%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.00(d,J=2.2Hz,1H),8.51(d,J=2.1Hz,1H),8.07(d,J=2.1Hz,1H),7.79(d,J=2.6Hz,1H),7.34–7.17(m,3H),7.11(d,J=2.1Hz,1H),6.98–6.93(m,1H),6.65–6.50(m,2H),5.49(s,1H),4.26(dd,J=10.6,2.6Hz,1H),3.98(dd,J=10.3,2.8Hz,1H),3.94–3.85(m,2H),3.69–3.59(m,2H),3.23–3.11(m,2H),2.73(td,J=13.3,12.6,3.6Hz,1H).
Example 13: preparation of Compound 13
Referring to the procedure for the synthesis of compound 2 in example 2, compound 13 (129 mg, 18.0%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ11.96(s,1H),8.50(d,J=2.2Hz,1H),8.04(d,J=2.2Hz,1H),7.72(s,1H),7.19(dd,J=8.4,2.2Hz,1H),7.08(d,J=2.2Hz,1H),6.96(d,J=8.6Hz,1H),4.26(dd,J=10.6,2.5Hz,1H),3.99(dd,J=10.5,3.0Hz,1H),3.95–3.83(m,2H),3.71–3.59(m,2H),3.56(s,2H),3.22–3.12(m,2H),2.78–2.69(m,1H).
Example 14: preparation of Compound 14
Referring to the procedure for the synthesis of compound 2 in example 2, compound 14b (310 mg, 26.1%) was obtained as a white solid.
To CH of compound 14b (300 mg,0.63 mmol) with stirring 3 To a solution of OH (1.0 mL) was added dropwise dioxane hydrochloride (4N, 3.5 mL). After the addition, the reaction was stirred at room temperature overnight. Concentrating the reaction solution under reduced pressure, and dissolving the obtained solid in H 2 In O, DCM was washed once. Then under ice bath, go to H 2 Slowly adding a proper amount of sodium hydroxide (NaOH) solid particles into the O solution, collecting the precipitated solid product by suction filtration, and using H to prepare a filter cake 2 And (3) washing. The crude product obtained was purified by column chromatography on silica gel (DCM/CH 3 OH system elution) to give compound 14 (105 mg, 44.4% yield) as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.07(s,1H),8.65(d,J=2.3Hz,1H),8.50(d,J=2.2Hz,1H),7.96(s,1H),7.14(dd,J=8.4,2.1Hz,1H),7.03(d,J=2.1Hz,1H),6.97(d,J=8.5Hz,1H),4.26(dd,J=10.6,2.5Hz,1H),4.03–3.85(m,5H),3.63(tt,J=11.4,5.6Hz,2H),3.23–3.12(m,2H),2.94(t,J=8.1Hz,2H),2.73(td,J=12.1,3.5Hz,1H),1.90(p,J=7.7Hz,2H).
Example 15: preparation of Compound 15
Referring to the procedure for the synthesis of compound 2 in example 2, compound 15b (177 mg, 18.1%) was obtained as a white solid.
Referring to the procedure for the synthesis of compound 14 in example 14, compound 15 (70 mg, 51.8%) was obtained as a white solid. 1 HNMR(500MHz,DMSO-d 6 )δ12.12(s,1H),10.09(s,1H),8.56(s,1H),8.13(s,1H),7.89(d,J=2.6Hz,1H),7.63(d,J=8.6Hz,2H),7.52(dd,J=8.9,2.1Hz,2H),7.22(dd,J=8.4,2.1Hz,1H),7.13(d,J=2.1Hz,1H),6.96(d,J=8.6Hz,1H),4.26(dd,J=10.6,2.5Hz,1H),3.98(dd,J=10.8,3.1Hz,1H),3.94–3.85(m,2H),3.69–3.59(m,2H),3.23–3.12(m,2H),2.73(td,J=11.3,10.8,3.4Hz,1H),2.06(s,3H).
Example 16: preparation of Compound 16
To a solution of compound 10 (84 mg,0.2 mmol) and triethylamine (40 mg,0.4 mmol) in DCM (2.0 mL) under ice-bath was slowly added dropwise acetyl Chloride (CH) 3 COCl,16mg,0.2 mmol). After the addition, the reaction solution was stirred in an ice bath until the starting material disappeared. The reaction solution was diluted with an appropriate amount of DCM, washed three times with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to give compound 16 (40 mg, 43.1% yield) as a pale yellow solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.37–12.03(m,1H),9.55(s,1H),8.56(s,1H),8.29(d,J=1.7Hz,1H),7.95(d,J=2.5Hz,1H),7.76(t,J=7.1Hz,1H),7.57(dd,J=7.7,1.2Hz,1H),7.38–7.31(m,1H),7.25(dd,J=8.4,1.9Hz,1H),7.21–7.14(m,2H),6.97(d,J=8.6Hz,1H),4.27(dd,J=10.6,2.5Hz,1H),3.99(dd,J=11.1,3.1Hz,1H),3.94–3.85(m,2H),3.72–3.57(m,2H),3.23–3.12(m,2H),2.74(td,J=11.8,3.5Hz,1H),2.16(s,3H).
Example 17: preparation of Compound 17
Referring to the procedure for the synthesis of compound 16 in example 16, compound 17 (42 mg, 45.3%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.25–12.10(m,1H),10.03(s,1H),8.55(s,1H),8.12(d,J=1.6Hz,1H),7.96(d,J=2.7Hz,1H),7.85(s,1H),7.52(d,J=8.0Hz,1H),7.33(t,J=7.9Hz,1H),7.28–7.21(m,2H),7.13(d,J=2.1Hz,1H),6.97(d,J=8.6Hz,1H),4.27(dd,J=10.6,2.5Hz,1H),4.01–3.87(m,3H),3.70–3.59(m,2H),3.23–3.12(m,2H),2.74(td,J=11.4,11.0,3.4Hz,1H),2.07(s,3H).
Example 18: preparation of Compound 18
Referring to the procedure for the synthesis of compound 16 in example 16, compound 18 (39 mg, 42.0%) was obtained as a white solid. 1 HNMR(500MHz,DMSO-d 6 )δ12.13(s,1H),10.09(s,1H),8.56(s,1H),8.14(s,1H),7.89(d,J=2.6Hz,1H),7.63(d,J=8.6Hz,2H),7.52(dd,J=8.9,2.1Hz,2H),7.23(dd,J=8.4,2.1Hz,1H),7.13(d,J=2.1Hz,1H),6.97(d,J=8.6Hz,1H),4.27(dd,J=10.6,2.5Hz,1H),4.02–3.85(m,3H),3.70–3.59(m,2H),3.23–3.12(m,2H),2.74(td,J=11.3,10.8,3.4Hz,1H),2.07(s,3H).
Example 19: preparation of Compound 19
Referring to the procedure for the synthesis of compound 16 in example 16, compound 19 (50 mg, 62.2%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ12.03(d,J=2.2Hz,1H),8.51(d,J=2.1Hz,1H),8.38(t,J=5.0Hz,1H),8.02(d,J=2.0Hz,1H),7.78(d,J=2.7Hz,1H),7.19(dd,J=8.4,2.1Hz,1H),7.08(d,J=2.2Hz,1H),6.97(d,J=8.6Hz,1H),4.27(dd,J=10.6,2.5Hz,1H),4.17(d,J=5.3Hz,2H),3.99(dd,J=10.7,3.1Hz,1H),3.95–3.82(m,2H),3.72–3.56(m,2H),3.23–3.12(m,2H),2.74(td,J=11.2,10.6,3.4Hz,1H),1.86(s,3H).
Example 20: preparation of Compound 20
Referring to the procedure for the synthesis of compound 2 in example 2, compound 20 (22 mg, 11.3%) was obtained as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ11.99(s,1H),8.56(s,1H),7.99(s,1H),7.74(s,1H),7.18(dd,J=8.4,2.1Hz,1H),7.07(d,J=2.1Hz,1H),6.97(d,J=8.5Hz,1H),5.41(s,1H),4.27(dd,J=10.6,2.5Hz,1H),4.04–3.85(m,3H),3.72–3.58(m,2H),3.24–3.10(m,2H),2.73(td,J=13.2,12.5,3.5Hz,1H),1.51(s,6H).
Example 21: preparation of Compound 21
To compound 1e (5.40 g,20.00 mmol), bis-pinacolato diboron (10.16 g,40.00 mmol) and KOA C (5.88 g,60.00 mol) of dioxane (54.0 mL) was purged with a nitrogen stream to empty the reaction solution of air (15 min), and then catalyst Pd (PPh) 3 ) 4 (1.16 g,1.00 mmol). After the addition, the reaction mixture was heated to 95℃in a closed system and stirred overnight. The reaction solution was cooled to room temperature, the solution was concentrated under reduced pressure, the resulting solid was dissolved in DCM, washed twice with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 The OH system eluted) to give compound 21a as a white solid (2.74 g,yield 43.2%).
To compound 21b (411 mg,3.00 mmol) and compound 21c (450 mg,2.00 mmol) were added dioxane (dioxane, 5.0 mL) and piperidine (5.0 mL) TEA (768 mL,7.6 mmol). After the addition, the reaction mixture was heated to 100℃in a closed system and stirred overnight. The reaction solution was cooled to room temperature, the solution was concentrated under reduced pressure, the resulting solid was dissolved in DCM, washed twice with water and then once with saturated brine, and the organic phase was taken up in anhydrous Na 2 SO 4 And (5) drying. The drying agent was removed by filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to afford compound 21d (471 mg, 78.5% yield) as a pale yellow solid.
The procedure for the synthesis of 1g of compound of example 1 was followed to give compound 21 (66 mg, yield 32.2%) as a white solid. 1 HNMR(500MHz,DMSO-d 6 )δ11.92(d,J=2.7Hz,1H),8.80(d,J=2.3Hz,1H),8.55(d,J=2.1Hz,1H),8.49(d,J=2.1Hz,1H),8.39(dd,J=4.7,1.6Hz,1H),8.04(dt,J=8.0,2.0Hz,1H),7.82(d,J=2.6Hz,1H),7.58(d,J=16.7Hz,1H),7.37(dd,J=8.0,4.7Hz,1H),7.26(dd,J=8.4,2.2Hz,1H),7.23–7.16(m,2H),6.98(d,J=8.5Hz,1H),4.28(dd,J=10.6,2.6Hz,1H),3.99(dd,J=11.1,3.4Hz,1H),3.95–3.87(m,2H),3.71–3.60(m,2H),3.21(t,J=10.5Hz,1H),3.17–3.11(m,1H),2.74(td,J=11.6,3.6Hz,1H).
Example 22: preparation of Compound 22
To a solution of compound 22b (427 mmol,2.40 mmol) in dichloromethane (4.0 mL) was added a solution of compound 22a (424 mg,2.00 mmol) in pyridine (4.0 mL). The reaction mixture was stirred at room temperature overnight. The precipitate was collected by filtration and the resulting crude product was purified by silica gel column chromatography (DCM/CH 3 OH system elution) to afford compound 22c as a brown solid (311 mg, 40.8% yield).
The procedure for the synthesis of 1g of compound of example 1 was followed to give compound 22 (112 mg, yield 32.8%) as a white solid. 1 H NMR(500MHz,DMSO-d 6 )δ11.51(d,J=2.6Hz,1H),10.51(s,1H),9.17(d,J=1.5Hz,1H),8.77(dd,J=4.7,1.7Hz,1H),8.55(d,J=2.2Hz,1H),8.49(d,J=2.2Hz,1H),8.35(dt,J=7.9,2.0Hz,1H),7.95(d,J=2.6Hz,1H),7.59(dd,J=7.5,5.2Hz,1H),7.19(dd,J=8.4,2.2Hz,1H),7.09(s,1H),6.97(d,J=8.5Hz,1H),4.26(dd,J=10.6,2.6Hz,1H),3.98(dd,J=10.6,3.4Hz,1H),3.94–3.86(m,2H),3.69–3.59(m,2H),3.20(t,J=10.5Hz,1H),3.14(tt,J=10.7,2.5Hz,1H),2.73(td,J=11.3,10.7,3.5Hz,1H).
Example 23: partial compound in vitro AAK1 inhibition activity assay
1. Experimental materials
AAK1(Innitrogen,Cat.No.A32880);LP-922761(MCE,Cat.No.HY-120179);ADP-Glo KinaseAssay(Promege,Cat.No.v9102/3);HEPES,pH7.5(Gibco,Cat.No.11344-041);Brij-35solution(Sigma,Cat.No.B4184);EDTA(Gibco,Cat.No.15575-038);MgCl 2 (Sigma,Cat.No.M2670-500g);DTT(Sigma,Cat.No.D0632-10G);96well plate(Corning,Cat.No.3365);384well Echo plate(Labcyte,Cat.No.PP-0200);PROXIPLATE-384PLUS(PE,Cat.No.6008289)。
2. Experimental method
2.1 serial dilution of Compounds to prepare Source plate
1) The initial concentration of the compound tested was 0.5. Mu.M, formulated at a 100-fold concentration, i.e., 50. Mu.M. 995. Mu.L of 100% DMSO was added to the EP tube, followed by 5. Mu.L of 10mM compound solution, to prepare a 50. Mu.M compound solution. mu.L of the above compound solution was added to the second well of the 96-well plate, and 80. Mu.L of 100% DMSO was added to the other wells. Adding 20 mu L of compound solution from the second hole into the third hole, sequentially diluting downwards for 5 times, and diluting for 4 concentrations;
2) 100 μl of 100% dmso was added as a no compound control and no enzyme control, respectively, to the same 96 well plate, and the plate was labeled as a source plate;
2.2 preparation of intermediate plate
Transfer 40 μl of compound from the source plate onto a new 384 well plate as an intermediate plate;
2.3 preparation of analysis plate
Transfer 50nL of compound to assay plate by Echo in 100% dmso;
2.4 preparation of buffer solution
40mM Tris pH 7.5,20mM MgCl 2 ,0.01mg/ml BSA,1mM DTT;
2.5 preparation of kinase solution
1) Preparing an AAK1 solution in a kinase buffer;
2) 2.5. Mu.L of kinase solution was added per well except for the control wells without enzyme (replaced with 2.5. Mu.L of kinase buffer);
3) A rocking plate;
2.6 preparation of substrate solution
1) Preparing a substrate solution of an AAK1 peptide substrate and ATP in a 1x kinase reaction buffer;
2) 2.5. Mu.L of substrate solution was added to each well of the assay plate to initiate the reaction;
3) A rocking plate;
2.7 kinase reaction
The assay plate was covered and incubated for 1 hour at room temperature;
2.8 kinase assay
1) Equilibrate ADP-Glo reagent to room temperature;
2) The reaction was stopped by adding 5. Mu.L of ADP-Glo reagent per well;
3) Stirring with a centrifuge, slowly shaking on a shaking table, and balancing for 120 min;
4) Adding 10 mu L of kinase detection reagent into each hole, oscillating for 1min, balancing for 30min, and reading and emitting light on a flat-plate reader;
2.9 reading of the plate
Collecting data;
2.10 Curve fitting
1) Copying the value of the RLU from Envision;
2) Converting the RLU value to a percent inhibition value;
a. inhibition ratio = (max-sample RLU)/(max-min) ×100;
"min" refers to RLU without enzyme, "max" refers to RLU with DMSO;
3) Fitting the data in XLFIT excel 5.4.0.8 version to obtain IC 50 A value;
the formula is Y =Bottom+(Top-Bottom)/(1+(IC 50 /X)*HillSlope);
Top is the highest point of the curve, bottom is the lowest point of the curve, hillSlope represents the curvature of the curve.
3. Experimental results
Inhibition of AAK1 by a portion of the target compounds was determined by the above-described experimental methods. The results are shown in Table 1.
TABLE 1 half inhibition concentration of target compounds on AAK1
Example 24: compound 4, 9 inhibiting SARS-CoV-2 pseudovirus from infecting ACE2 high expression cell
1. Cells and viruses used in experiments
SARS-CoV-2 pseudovirus is purchased from Biotechnology Co., ltd. In Fubai, and has a product number of FNV215, and the surface of the envelope of the virus contains Spike glycoprotein (Spike Protein) of a novel coronavirus, and the virus is internally coated with RNA sequences of Green Fluorescent Protein (GFP) and Luciferase (Luciferase). The infection efficiency can be judged by observing the expression of green fluorescent protein and detecting the activity of luciferase after the virus infects target cells 48-72H.
The HEK-293 cell line hACE2-HEK293 overexpressing human ACE2 protein was also purchased from Biotechnology Co., ltd., fubai, st. No. FBC2591, and the cell culture broth was DMEM medium containing 10% FBS, 1% Streptomyces lividans mixed solution according to conventional subculture.
2. Experimental procedure and results:
2.1 drug treatment:
the drug to be tested was diluted to 10mM with DMSO, then the 10mM drug solution was diluted to 1mM with cell culture solution (dulbecco' smodified eagle medium, DMEM), sterilized and filtered through a 0.22 μm filter, and sub-packaged and stored at-20deg.C for use.
2.2 evaluation of the effect of drugs on invasion of SARS-CoV-2 into host cells:
hACE2-293 cells were cultured at a density of 5X 10 5 Inoculating into 24-well plate at 37deg.C with 5% CO 2 After the cells are completely adhered after being cultured for 6 hours in an incubator. hACE2-HEK293 cells were treated with 5. Mu.M of compounds 4 and 9 in DMEM, 5. Mu.M of LX9211 was added as a positive control group, 5. Mu.M of compound 28 (J.Med. Chem.2019,62, 5810-5831) was added as a reference group, cells treated without any drug were used as a negative control group, and after 1 hour of drug treatment, SARS-CoV-2 pseudovirus (MOI=5) was added and cells were continuously infected at 37℃for 48 hours. The green fluorescent protein expression was observed by photographing under a fluorescent microscope, and the result is shown in fig. 1. After photographing, cells were lysed and the luminescence value of luciferases was measured using the Luciferase Assay System kit (Promega Co.) and the results are shown in FIG. 2.
Wherein the structure of compound 28 is shown in the formula:
FIG. 1 shows that compounds 4, 9, 28 and LX9211 (BMS-986176) inhibit SARS-CoV-2 virus invasion into host cells as measured by 50 μm when green fluorescent protein expression is observed under a fluorescent microscope.
The luciferase assay of fig. 2 shows that compounds 4, 9, 28 and LX9211 (BMS-986176) inhibit invasion of SARS-CoV-2 virus into host cells with P <0.01.
Experimental results show that the AAK1 inhibitor obtained through structural modification, the compounds 4 and 9 can enhance the activity of corresponding SARS-CoV-2 virus invasion host cells, and can be used for preventing or treating related diseases caused by novel coronavirus infection, and are expected to provide new candidate drug molecules for clinically treating pneumonia caused by the novel coronavirus infection and upper respiratory tract infection caused by the novel coronavirus infection.
In summary, the present invention provides the preparation of compounds of formula I, and their inhibition of AAK1 and their use in the preparation of anti-coronavirus drugs.
Claims (12)
1. An AAK1 inhibitor compound, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, characterized in that the structural formula of the compound is shown in formula (I):
x in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole;/>represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
2. An AAK1 inhibitor compound according to claim 1, or an optical isomer, racemate, single enantiomer, possible diastereoisomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, wherein X in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the position of attachment of X to 7-azaindoleA dot; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
3. An AAK1 inhibitor compound according to claim 2, or an optical isomer, racemate, single enantiomer, possible diastereoisomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, wherein X in formula (I) is selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents X linked to 7-azaindoleIs a site of (2); />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
4. An AAK1 inhibitor compound according to claim 1, wherein the compound has the structural formula of any one of formulae 1 to 27:
5. a process for preparing an AAK1 inhibitor compound, characterized in that when x=When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out a Sonogashira reaction on the compound h and the compound i to obtain a compound Ia;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3; y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
6. A process for preparing an AAK1 inhibitor compound, characterized in that when x=When the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out a Sonogashira reaction on the compound h and the compound i to obtain a compound Ia;
(7) The compound Ia is subjected to reduction reaction to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3, y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Representation ofThe site where Y is linked to Z.
7. A process for preparing an AAK1 inhibitor compound, characterized in that whenWhen the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) The compound e is subjected to Miyaurabelation reaction to obtain a compound f;
(5) Reacting the compound g with the compound h through decarboxylative Knoevenagel to obtain a compound i;
(6) Carrying out Suzuki reaction on the compound f and the compound I to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3, y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
8. A process for preparing an AAK1 inhibitor compound, characterized in that whenWhen the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) Carrying out Sandmeyer reaction on the compound d to obtain a compound e;
(4) The compound e is subjected to Miyaurabelation reaction to obtain a compound f;
(5) Carrying out amide coupling reaction on the compound g and the compound h to obtain a compound i;
(6) Carrying out Suzuki reaction on the compound f and the compound I to obtain a compound I;
the synthetic route is as follows:
wherein Y is selected from one of the following structures:
wherein n is a natural number from 1 to 3, y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
9. A process for preparing an AAK1 inhibitor compound, characterized in that whenWhen the method comprises the following steps:
(1) Carrying out substitution reaction on the compound a and the compound b to obtain a compound c;
(2) The compound c undergoes a reduction reaction to obtain a compound d;
(3) The compound d undergoes bromine substitution reaction to obtain a compound e;
(4) Carrying out Suzuki reaction on the compound e and the compound f to obtain a compound g;
(5) Halogenating the compound g and N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS) to obtain a compound h;
(6) Carrying out Suzuki reaction on the compound h and the compound i to obtain a compound Ib;
the synthetic route is as follows:
wherein,selected from one of the following structures:
y is selected from one of the following structures:
wherein n is a natural number from 1 to 3, y=0 or 1;
z is selected from one of the following structures:
z=0 or 1;
wherein the method comprises the steps ofRepresents the site of attachment of X to 7-azaindole; />Represents the site of attachment of X to Y; />Represents the site where Y is linked to Z.
10. Use of an AAK1 inhibitor compound according to any one of claims 1-4, or an optical isomer, racemate, single enantiomer, possible diastereoisomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof, for the preparation of an anti-coronavirus drug.
11. An anti-coronavirus agent comprising a safe and effective amount of said AAK1 inhibitor compound, or an optical isomer, racemate, single enantiomer, possible diastereomer, or a pharmaceutically acceptable salt, prodrug, deuterated derivative, hydrate, solvate thereof.
12. An anti-coronavirus agent according to claim 9, further comprising a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2023100357624 | 2023-01-10 | ||
CN202310035762 | 2023-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117865993A true CN117865993A (en) | 2024-04-12 |
Family
ID=90576687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410031946.8A Pending CN117865993A (en) | 2023-01-10 | 2024-01-09 | AAK1 inhibitor and preparation and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117865993A (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016197987A1 (en) * | 2015-06-12 | 2016-12-15 | 杭州英创医药科技有限公司 | Heterocyclic compound serving as syk inhibitor and/or syk-hdac dual inhibitor |
WO2018108084A1 (en) * | 2016-12-12 | 2018-06-21 | 杭州英创医药科技有限公司 | Compound containing tricyclic heteroaryl group |
WO2020188467A1 (en) * | 2019-03-15 | 2020-09-24 | 杭州英创医药科技有限公司 | Condensed tricyclic compound used as kinase inhibitor |
CN112239473A (en) * | 2019-07-17 | 2021-01-19 | 百济神州(北京)生物科技有限公司 | Tricyclic compounds as HPK1 inhibitors |
WO2021043152A1 (en) * | 2019-09-03 | 2021-03-11 | 微境生物医药科技(上海)有限公司 | Pyrimidine derivative as wee1 inhibitor |
WO2021213317A1 (en) * | 2020-04-20 | 2021-10-28 | 微境生物医药科技(上海)有限公司 | Hpk1 inhibitor, preparation method therefor and use thereof |
CN115353512A (en) * | 2021-07-30 | 2022-11-18 | 上海翊石医药科技有限公司 | Heterocyclic urea compound and preparation method and application thereof |
CN115490699A (en) * | 2021-06-19 | 2022-12-20 | 成都海博为药业有限公司 | Fused ring compound and pharmaceutical composition and application thereof |
-
2024
- 2024-01-09 CN CN202410031946.8A patent/CN117865993A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016197987A1 (en) * | 2015-06-12 | 2016-12-15 | 杭州英创医药科技有限公司 | Heterocyclic compound serving as syk inhibitor and/or syk-hdac dual inhibitor |
WO2018108084A1 (en) * | 2016-12-12 | 2018-06-21 | 杭州英创医药科技有限公司 | Compound containing tricyclic heteroaryl group |
WO2020188467A1 (en) * | 2019-03-15 | 2020-09-24 | 杭州英创医药科技有限公司 | Condensed tricyclic compound used as kinase inhibitor |
CN112239473A (en) * | 2019-07-17 | 2021-01-19 | 百济神州(北京)生物科技有限公司 | Tricyclic compounds as HPK1 inhibitors |
WO2021043152A1 (en) * | 2019-09-03 | 2021-03-11 | 微境生物医药科技(上海)有限公司 | Pyrimidine derivative as wee1 inhibitor |
WO2021213317A1 (en) * | 2020-04-20 | 2021-10-28 | 微境生物医药科技(上海)有限公司 | Hpk1 inhibitor, preparation method therefor and use thereof |
CN115490699A (en) * | 2021-06-19 | 2022-12-20 | 成都海博为药业有限公司 | Fused ring compound and pharmaceutical composition and application thereof |
CN115353512A (en) * | 2021-07-30 | 2022-11-18 | 上海翊石医药科技有限公司 | Heterocyclic urea compound and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7079527B2 (en) | Intracyclic thiamidinoamide-arylamide compounds and their uses for the treatment of hepatitis B | |
CN108250122B (en) | Sulfonamide-aryl amide compounds and pharmaceutical use thereof for treating hepatitis B | |
ES2648094T3 (en) | Dual selective PI3 kinase delta and gamma inhibitors | |
CN108794487B (en) | Bicyclic nucleocapsid inhibitors and their use as medicaments for the treatment of hepatitis b | |
CN108264520B (en) | Compound for treating hepatitis B and application thereof | |
JP2002509140A (en) | Triazine antiviral compounds | |
JPH05202045A (en) | 1,3-oxathiolane useful for treating hepatitis | |
CN114437077B (en) | Compounds useful as kinase inhibitors and uses thereof | |
CN115043842A (en) | Amino-substituted bicyclic inhibitor and preparation method and application thereof | |
CN108341817B (en) | Thiourea, urea compound and use thereof | |
EA023907B1 (en) | Macrocyclic compounds and methods for their production | |
WO2024008129A1 (en) | Compound as kat6 inhibitor | |
CN113286798B (en) | Ensultiamidinamide-aryl amide compound and application thereof in treating hepatitis B | |
WO2018153326A1 (en) | Sulfonyl hydrazine compound and use thereof | |
CN117865993A (en) | AAK1 inhibitor and preparation and application thereof | |
US11834451B2 (en) | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | |
CN112074518B (en) | Di-parallel cyclic urea nucleocapsid inhibitor and its pharmaceutical use | |
CN108341810B (en) | Episulfide urea compound and application thereof | |
CN109251158B (en) | Thioamidine amide compounds and use thereof for treating hepatitis B | |
WO2020151296A1 (en) | Dinucleotide precursor for drug and preparation method therefor | |
CN112074504B (en) | Di-heterocyclic nuclear capsid inhibitor and pharmaceutical use thereof | |
CN115677698B (en) | High-efficiency antiviral compound and application thereof | |
CN112851679B (en) | 2, 4, 7-trisubstituted pyrimidoindole compound with antitumor effect | |
CN118373765A (en) | Coronavirus inhibitors and uses thereof | |
JPH04356466A (en) | New quinoline derivative and carcinostatic agent effect enhancer containing the derivative as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |